NCT04656795

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

A Single Dose, Non-Randomized, Open-Label, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of MT-7117 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Tanabe Pharma America, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This is an open-label, non randomised, single-dose, study in male and female subjects with renal impairment (severe and if required mild \& moderate) compared to male and female subjects with normal renal function.

Conditions

• Renal Impairment
• Normal Renal Function

Interventions

Type	Name	Description
DRUG	MT-7117	MT-7117

Timeline

• Start date: 2020-12-02
• Primary completion: 2021-12-04
• Completion: 2021-12-09
• First posted: 2020-12-07
• Last updated: 2023-05-15

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study